OptiNose, Inc. (OPTN)

Market Cap	55.35M
Revenue (ttm)	75.67M
Net Income (ttm)	-31.15M
Shares Out	150.83M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,301,771
Open	0.339
Previous Close	0.339
Day's Range	0.321 - 0.463
52-Week Range	0.321 - 2.100
Beta	-0.07
Analysts	Strong Buy
Price Target	3.00 (+717.44%)
Earnings Date	Nov 12, 2024

About OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a l...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Oct 13, 2017
• Employees: 132
• Stock Exchange: NASDAQ
• Ticker Symbol: OPTN
• Website: https://www.optinose.com

Financial Performance

In 2023, OptiNose's revenue was $70.99 million, a decrease of -6.93% compared to the previous year's $76.28 million. Losses were -$35.48 million, -52.58% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for OPTN stock is "Strong Buy." The 12-month stock price forecast is $3.0, which is an increase of 717.44% from the latest price.

Price Target

$3.0

(717.44% upside)

Analyst Consensus: Strong Buy